Evidence map›Paper›PMID 28899969›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression.

Neal R Godse, Nayel Khan, Zachary A Yochum, Roberto Gomez-Casal, Carolyn Kemp, Daniel J Shiwarski, Raja S Seethala, Scott Kulich, Mukund Seshadri, Timothy F Burns and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. The role of anoctamin 1 in liver disease.Journal of cellular and molecular medicine · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Role of ANO1 in tumors and tumor immunity.Journal of cancer research and clinical oncology · 2022
    Review
  18. Article
  19. TMEM16A as a potential treatment target for head and neck cancer.Journal of experimental & clinical cancer research : CR · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Neal R GodseUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Nayel KhanDepartment of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Zachary A YochumUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Roberto Gomez-CasalDepartment of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Carolyn KempDepartment of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Daniel J ShiwarskiDepartment of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Raja S SeethalaDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Scott KulichDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Mukund SeshadriDepartment of Head and Neck Surgery, Roswell Park Cancer Institute, Buffalo, New York.
Timothy F BurnsUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Umamaheswar DuvvuriUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. duvvuriu@upmc.edu.
University of Pittsburgh · USUniversity of Pittsburgh Medical Center · USRoswell Park Comprehensive Cancer Center · USUPMC Health System · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 2004 to 2026
$49.6M
Determining the Mechanisms of TWIST1-mediated Crizotinib Resistance in MET-driven Non-Small Cell Lung CarcinomaF30CA213765 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YOCHUM, ZACHARY · 2017 to 2019
$148k
Novel targets to treat head and neck cancer in VeteransI01BX003456 · VA · VETERANS HEALTH ADMINISTRATION · PI DUVVURI, UMAMAHESWAR · 2017 to 2021
–
BLRD VA CDA-2-057-10SBLRD VA I01 BX003456NCI NIH HHS F30 CA213765NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsAnoctamin-1Antineoplastic AgentsApoptosisBcl-2-Like Protein 11Carcinoma, Squamous CellCell Line, TumorCisplatinDown-RegulationFemaleHead and Neck NeoplasmsHumansMaleMice, NudeMiddle AgedANO1 protein, humanAnoctamin-1Antineoplastic AgentsBcl-2-Like Protein 11CisplatinNeoplasm Proteins

Identifiers

PMID28899969
PMCPMC5898434
OpenAlexW2754848079

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.